ADC · HER2+ 유방암

13개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved13 programs
ADCStandard DatabasestaleRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#Popular#antibody-drug-conjugate+4
Trials 127Status Discontinued
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 124Status Recruiting
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 122Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin(RC48) Plus Tratuzumab)

HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 91Status Recruiting
ADCStandard DatabasestaleRocheDM1 via butelase-1 with ABD…Phase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1)

HER2 Positive Breast Carcinoma; Recurrent Breast Carcinoma · HER2

#HER2#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 57Status Active
ADCStandard DatabasestaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#antibody-drug-conjugate#Byondis
Trials 23Status Active
ADCStandard DatabasestaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SalivaryGlandCarcinoma+2
Trials 23Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCStandard DatabasestaleQuantumLeap Healthcare Collabor…Phase 2

[vic-]trastuzumab duocarmazine (SYD985, SYD985 ([vic-]trastuzumab duocarmazine))

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 7Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Plus Cadonilimab)

Bile Duct Adenocarcinoma Non-Resectable; HER2 Gene Mutation · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BileDuctAdenocarcinomaNon-Resect+2
Trials 6Status Active
ADCStandard DatabasestaleMacroGenicsPhase 2

vobramitamab duocarmazine (vobramitamab duocarmazine)

Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+2
Trials 3Status Discontinued
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#antibody-drug-conjugate#HER2-negativeBreastCancer+2
Trials 1Status Recruiting